bluebird bio Garners $60,000,000 Series D Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7b1864ce-f8cb-4712-a21c-be9ad0d564a4&Preview=1 -
Date
7/25/2012 -
Company Name
bluebird bio -
Mailing Address
840 Memorial Drive Cambridge, MA 02139 -
Company Description
bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. -
Website
http://www.bluebirdbio.com -
Transaction Type
Venture Equity -
Transaction Amount
$60,000,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds will be used to advance the company’s clinical programs in severe genetic disorders, including childhood cerebral adrenoleukodystrophy (CCALD), beta-thalassemia and sickle cell disease. -
M&A Terms
-
Venture Investor
Deerfield Capital -
Venture Investor
RA Capital -
Venture Investor
Shire Pharmaceuticals -
Venture Investor
Undisclosed
